Impact of Personalized Dosing of Faricimab on Treatment Outcomes in nAMD

Video

Dr Varun Chaudhary discusses the impact of personalized treat-and-extend-based dosing on visual and anatomic outcomes of faricimab in the TENAYA and LUCERNE clinical trials in neovascular AMD.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

      Subscribe Now!
      Recent Videos
      3 experts are featured in this series.
      Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies
      Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
      Angiogenesis 2025: The global forecast for AI-driven home OCT
      3 experts are featured in this series.
      Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients
      3 experts are featured in this series.
      Perspectives on the Usefulness of Real-world Data
      3 experts are featured in this series.
      Safety Profile of New Therapies
      3 experts are featured in this series.
      Outcomes with Raricimab and Choosing Between the New Therapies
      3 experts are featured in this series.
      Faricimab Molecular Design and Role of Ang-2
      3 experts are featured in this series.
      Patient Selection for Aflibercept 8 mg
      3 experts are featured in this series.
      Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg
      3 experts are featured in this series.
      Significance of the Higher Molar Dose of Aflibercept 8 mg
      Related Content
      The Agência de vigilância Sanitária (ANVISA) in Brazil. Concept image for pharmaceutical approval, Lucentis ranibizumab biosimilar ranivisio FYB201. Image credit: ©Rmcarvalhobsb – stock.adobe.com

      Brazil’s ANVISA grants marketing authorization to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG)

      Lynda Charters
      June 5th 2025
      Article

      The biopharmaceutical is the first biosimilar to ranibizumab (Genentech Inc.) approved in Brazil

      A bridge made from building blocks has an incomplete area. A hand reaches down with the missing block to close the gap. Concept image for age-related macular degeneration therapy and treatment article, IOL implantation and ophthalmology. Image credit: ©patpitchaya – stock.adobe.com

      An implantable option bridges the gap for patients with AMD

      Federico Badalà, MD
      June 4th 2025
      Article

      Long-term benefits and vision preservation using an extended macular vision IOL

      A pharmacist helps a customer access medication. Concept image for neovascular age-related macular degeneration eye drop treatment therapy. Image credit: ©Gorodenkoff – stock.adobe.com

      Topline results from investigational nAMD drop SYL1801 (Sylentis)

      Kassi Filkins
      May 19th 2025
      Article

      Three dose level cohorts of the small interfering RNA therapeutic were evaluated in a double-blind study

      A group of elderly women navigate a street in Europe. Concept image for age-related macular degeneration and geographic atrophy. Image credit: ©Zelma – stock.adobe.com

      How patients navigate quality-of-life challenges associated with geographic atrophy

      Lynda Charters
      May 15th 2025
      Article

      Investigators sought to understand the diagnostic path, symptoms, quality of life impact and coping mechanisms of patients with GA in western Europe and the United States

      Isarna Therapeutics shares positive results from Phase 2 BETTER trial

      Isarna Therapeutics shares positive results from Phase 2 BETTER trial

      Sydney M Crago
      May 7th 2025
      Article
      Two hands reach towards a logo which says "AI," for artificial intelligence. Concept image for AI screenings for neovascular age-related macular degeneration. Image credit: ©deagreez – stock.adobe.com

      Artificial intelligence analyses biomarker changes in neovascular AMD treated with faricimab

      Lynda Charters
      April 17th 2025
      Article

      The phase 3 LUCERNE and TENAYA trials suggested that faricimab may allow clinicians to extend the interval between injections to up to 16 weeks after an initial loading phase

      © 2025 MJH Life Sciences

      All rights reserved.